A Prospective Multi-Centre Trial Validating Flow Cytometric Minimal Residual Disease (Mrd) Pre And Post Allograft For Acute Myeloid Leukaemia (AML)

Not Applicable

• Conditions: Acute Myeloid Leukaemia; Cancer - Leukaemia - Acute leukaemia

• Registration Number: ACTRN12616001613493
• Lead Sponsor: Peter MacCallum Cancer Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Patients over 18years who are scheduled for an allograft for acute myeloid leukaemia.

Exclusion Criteria

Persistent morphological disease

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To compare, in a prospective setting, the time to morphological relapse (TTMR) between patients who are MRD+ at a specific time point, and those who are MRD- at that time point.<br><br>MRD will be performed by flow cytometric methods on a sample of bone marrow. The TTMR will be assessed by review of medical records. Morphological remission will be determined in accordance with standard of care by the treating hospital.[1, 3 and 6 months post allograft.]